Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | HTR1D | P28221 | 2/20 | 0.45 |
| ▸ | HTR2C | P28335 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.45 |
| ▸ | HTR3B | O95264 | 1/20 | 0.45 |
| ▸ | HTR3A | P46098 | 1/20 | 0.45 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.45 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.44 |
| ▸ | NCF1 | P14598 | 1/20 | 0.44 |
| ▸ | LCAT | P04180 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3658533 | 0.98 | ADRB1 (0.49) | ADRB1POLBEPHX2HTR1DHTR2C | |
| Hydrochloric Acid SCHEMBL25426101 | 0.98 | ADRB1 (0.49) | ADRB1POLBEPHX2HTR1DHTR2C | |
| SCHEMBL2365866 | 0.86 | ADRB1 (0.51) | ADRB1POLBEPHX2HTR1DHTR2C | |
| SCHEMBL18176128 | 0.85 | POLB (0.51) | POLBLCATNPC1RAB9ACXCR3 | |
| Tert-Butyl Formate SCHEMBL27727243 | 0.85 | SLC6A9 (0.42) | ADRB1POLBEPHX2HTR1DHTR2C | |
| SCHEMBL13107612 | 0.84 | SCN10A (0.51) | POLB | |
| SCHEMBL232841 | 0.83 | POLB (0.69) | POLBALDH1A1MAPTNPC1RAB9A | |
| SCHEMBL24970994 | 0.83 | ADRB1 (0.49) | ADRB1POLBEPHX2HTR1DHTR2C | |
| Hydrochloric Acid SCHEMBL31381852 | 0.83 | EPHX2 (0.56) | ADRB1POLBEPHX2HTR1DHTR2C | |
| Hydrochloric Acid SCHEMBL25310714 | 0.82 | POLB (0.68) | POLBALDH1A1MAPTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023139536-A1 | (4-PIPERAZIN-1YL)-4-ALKYL-PHTHALAZIN-1(2H)-ONE COMPOUNDS AS PARP7 INHIBITORS | RHIZEN PHARMACEUTICALS AG (CH) | 2023-07-27 | — | — | WO | disclosed |
| WO-2023062049-A1 | HETEROCYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-04-20 | — | — | WO | disclosed |
| US-20210246140-A1 | MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-08-12 | — | — | US | disclosed |
| US-20210246140-A1 | MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-08-12 | — | — | US | disclosed |
| WO-2021155196-A1 | MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 | THE GENERAL HOSPITAL CORPORATION (US) | 2021-08-05 | — | — | WO | disclosed |
| CN-105712952-B | 2-substituted oxy-5-methylsulfonyl phenyl piperazine amide analogue and preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2021-03-26 | — | — | CN | disclosed |
| CN-106397312-B | Method for preparing GLYT-1 inhibitor | 广东东阳光药业有限公司 | 2020-03-24 | — | — | CN | disclosed |
| CN-102762549-A | Phthalazinone derivative, and preparation method and pharmaceutical use thereof | SHANGHAI HENGRUI PHARM CO LTD | 2012-10-31 | — | — | CN | disclosed |
| CN-101622000-B | Method for synthesizing GLYT-1 inhibitors | HOFFMANN LA ROCHE | 2012-07-04 | — | — | CN | disclosed |
| CN-1874777-B | 1-(2-amino-benzoyl)-piperazine derivatives as glycine uptake inhibitors for the treatment of psychoses | HOFFMANN LA ROCHE | 2012-07-04 | — | — | CN | disclosed |
| CN-1874777-A | 1-(2-amino-benzoyl)-piperazine derivatives as glycine uptake inhibitors for the treatment of psychoses | HOFFMANN LA ROCHE (CH) | 2006-12-06 | — | — | CN | disclosed |
| CN-1867554-A | Piperazine with ortho-substituted phenyl and its use as GLYT1 inhibitors | HOFFMANN LA ROCHE (CH) | 2006-11-22 | — | — | CN | disclosed |
| WO-2006072435-A1 | SULFANYL SUBSTITUTED PHENYL METHANONES AS GLYCINE TRANSPORTER 1 (GLYT-1) INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-07-13 | — | — | WO | disclosed |
| US-20060149062-A1 | Sulfanyl substituted phenyl methanones | F. HOFFMANN-LA ROCHE AG (CH) | 2006-07-06 | — | — | US | disclosed |
| EP-1663232-A1 | 1-(2-AMINO-BENZOYL)-PIPERAZINE DERIVATIVES AS GLYCINE UPTAKE INHIBITORS FOR THE TREATMENT OF PSYCHOSES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-07 | — | — | EP | disclosed |
| EP-1656361-A1 | PIPERAZINE WITH OR-SUBSTITUTED PHENYL GROUP AND THEIR USE AS GLYT1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-05-17 | — | — | EP | disclosed |
| US-20050209241-A1 | Benzoyl-piperazine derivatives | HOFFMANN-LA ROCHE INC. | 2005-09-22 | — | — | US | disclosed |
| US-20050070539-A1 | Benzoyl-piperazine derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2005-03-31 | — | — | US | disclosed |
| WO-2005023260-A1 | 1- (2-AMINO-BENZOL) -PIPERAZINE DERIVATIVES AS GLYCINE UPTAKE INHIBITORS FOR THE TREATMENT OF PSYCHOSES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-03-17 | — | — | WO | disclosed |
| WO-2005014563-A1 | PIPERAZINE WITH OR-SUBSTITUTED PHENYL GROUP AND THEIR USE AS GLYT1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209241-A1 | Benzoyl-piperazine derivatives | SLC1A2, SLC18A2, SLC6A7 | ADRB1 630/4885POLB 2008/4885EPHX2 3608/4885 |
| US-20060149062-A1 | Sulfanyl substituted phenyl methanones | SULT1A1, SULT2A1, SULT1E1 | ADRB1 340/4885POLB 3437/4885EPHX2 2693/4885 |
| US-20210246140-A1 | MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 | GRM1, GRM2, GRIN1 | ADRB1 256/4885POLB 4739/4885EPHX2 3154/4885 |
| US-20050070539-A1 | Benzoyl-piperazine derivatives | OPRL1, ACHE, PNMT | ADRB1 97/4885POLB 1335/4885EPHX2 2966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.